What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes.

What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes.

What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes.


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Itamar Raz, MD

Itamar Raz, MD

Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel